YL201
YL201 is a pharmaceutical drug with 10 clinical trials. Currently 8 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
7
Early Stage
0
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
8
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Clinical Trials (10)
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
A Study of YL201 in Patients With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10